Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)
Open accessThe DOI matches its Crossref record; 384 of the 384 references it cites were found in a registry or an index.
Abstract
A panel of experts was convened by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) to update the 2010 clinical practice guideline on Clostridium difficile infection (CDI) in adults. The update, which has incorporated recommendations for children (following the adult recommendations for epidemiology, diagnosis, and treatment), includes significant changes in the management of this infection and reflects the evolving controversy over best methods for diagnosis. Clostridium difficile remains the most important cause of healthcare-associated diarrhea and has become the most commonly identified cause of healthcare-associated infection in adults in the United States. Moreover, C. difficile has established itself as an important community pathogen. Although the prevalence of the epidemic and virulent ribotype 027 strain has declined markedly along with overall CDI rates in parts of Europe, it remains one of the most commonly identified strains in the United States where it causes a sizable minority of CDIs, especially healthcare-associated CDIs. This guideline updates recommendations regarding epidemiology, diagnosis, treatment, infection prevention, and environmental management.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Clostridium difficile is a Gram‐positive extracellular pathogen, which remains localized to the gastrointestinal tract but can cause severe toxin‐mediated gastrointestinal pathology, with a mortality rate of up to 6%. 67 , 68”
From The battle for iron in enteric infections (2020) · cites this paper as [68]
Citations
Cites
Multistate point-prevalence survey of health care-associated infections
Magill, S. S., Edwards, J. R., Bamberg, W., Beldavs, Z. G., Dumyati, G., Kainer, M. A., Lynfield, R., Maloney, M., McAllister-Hollod, L., Nadle, J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1306801 · Cited by 3,931
Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708
Stool form scale as a useful guide to intestinal transit time
Lewis, S. J., & Heaton, K. W. (1997) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529709011203 · Cited by 3,244
Cohen, S. H., Gerding, D. N., Johnson, S., Kelly, C. P., Loo, V. G., McDonald, L. C., Pepin, J., & Wilcox, M. H. (2010) · Infection Control & Hospital Epidemiology · doi:10.1086/651706 · Cited by 2,942
Self-citationBurden of Clostridium difficile Infection in the United States
Lessa, F. C., Mu, Y., Bamberg, W. M., Beldavs, Z. G., Dumyati, G. K., Dunn, J. R., Farley, M. M., Holzbauer, S. M., Meek, J. I., Phipps, E. C., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1408913 · Cited by 2,641
Self-citationDethlefsen, L., Huse, S., Sogin, M. L., & Relman, D. A. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060280 · Cited by 2,361
An Epidemic, Toxin Gene–Variant Strain of Clostridium difficile
McDonald, L. C., Killgore, G. E., Thompson, A., Owens, R. C., Kazakova, S. V., Sambol, S. P., Johnson, S., & Gerding, D. N. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051590 · Cited by 2,006
Self-citationLoo, V. G., Poirier, L., Miller, M. A., Oughton, M., Libman, M. D., Michaud, S., Bourgault, A.-M., Nguyen, T., Frenette, C., Kelly, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051639 · Cited by 1,946
Self-citationGoing from evidence to recommendations
Guyatt, G. H., Oxman, A. D., Kunz, R., Falck-Ytter, Y., Vist, G. E., Liberati, A., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39493.646875.ae · Cited by 1,810
Fidaxomicin versus Vancomycin for Clostridium difficile Infection
Louie, T. J., Miller, M. A., Mullane, K. M., Weiss, K., Lentnek, A., Golan, Y., Gorbach, S., Sears, P., & Shue, Y.-K. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa0910812 · Cited by 1,585
Research works printed but not linked: 3
- Health Protection Agency, 2005, Outbreak of Clostridium difficile infection in a hospital in southeast England, CDR Wkly, 15
- Tleyjeh, 2012, Association between acid-suppression therapy and Clostridium difficile infection: a systematic review and meta-analysis, Clin Microbiol Infect, 18, 113
- Polage, 2015, Overdiagnosis of Clostridium difficile infection in the molecular test era, JAMA Intern Med, 175, 1792, 10.1001/jamainternmed.2015.4114 · DOI · Paper page
Cited by
Items 201–300 of 1,000
Tank, T. 2. G. I.-T., Zingg, W., Storr, J., Park, B. J., Ahmad, R., Tarrant, C., Castro‐Sánchez, E., Tomczyk, S. M., Kilpatrick, C., Allegranzi, B., et al. (2019) · Antimicrobial Resistance and Infection Control · doi:10.1186/s13756-019-0527-1 · Cited by 61
The Use of Fecal Microbiome Transplant in Treating Human Diseases: Too Early for Poop?
Ser, H., Letchumanan, V., Goh, B. H., Wong, S. H., & Lee, L. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.519836 · Cited by 63
Emergence of Clinical Clostridioides difficile Isolates With Decreased Susceptibility to Vancomycin
Darkoh, C., Keita, K., Odo, C., Oyaro, M., Brown, E. L., Arias, C. A., Hanson, B., & DuPont, H. L. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa912 · Cited by 62
Mullane, K. M., Winston, D. J., Nooka, A. K., Morris, M. I., Stiff, P. J., Dugan, M. J., Holland, H., Gregg, K., Adachi, J. A., Pergam, S. A., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy484 · Cited by 55
Self-citationImpact of the BioFire FilmArray gastrointestinal panel on patient care and infection control
Machiels, J. D., Cremers, A. J. H., van Bergen-Verkuyten, M. C., Paardekoper-Strijbosch, S. J. M., Frijns, K. C. J., Wertheim, H. F. L., Rahamat-Langendoen, J. C., & Melchers, W. J. G. (2020) · PLoS ONE · doi:10.1371/journal.pone.0228596 · Cited by 55
Khanna, S., Sims, M. D., Louie, T., Fischer, M., LaPlante, K. L., Allegretti, J. R., Hasson, B. R., Fonte, A. T., McChalicher, C. W. J., Ege, D. S., et al. (2022) · Antibiotics · doi:10.3390/antibiotics11091234 · Cited by 61
“The panel members expressed concerns about limitations in the evidence due to patient selection, prior treatments received, the duration of time from the last CDI episode, and risks of the transmission of emerging pathogens and/or microbes associated with acute and/or chronic infections [25,36].”
BackgroundSelf-citationUpdates in Treatment of Recurrent Clostridium difficile Infection
Singh, T., Bedi, P. S., Bumrah, K., Singh, J., Rai, M., & Seelam, S. (2019) · Journal of Clinical Medicine Research · doi:10.14740/jocmr3854 · Cited by 54
Lurienne, L., Bandinelli, P.-A., Galvain, T., Coursel, C.-A., Oneto, C., & Feuerstadt, P. (2020) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-020-0179-1 · Cited by 55
Allegretti, J. R., Kelly, C. R., Grinspan, A. M., Mullish, B. H., Hurtado, J., Carrellas, M., Marcus, J., Marchesi, J. R., McDonald, J. A. K., Gerardin, Y., et al. (2020) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izaa283 · Cited by 59
Self-citationBoekhoud, I. M., Sidorov, I. A., Nooij, S., Harmanus, C., Sanders, I. M. J. G., Viprey, V. F., Spittal, W. D., Clark, E., Davies, K., Freeman, J., et al. (2021) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkab097 · Cited by 56
Mechanisms of antibiotic resistance of Clostridioides difficile
Wickramage, I., Spigaglia, P., & Sun, X. (2021) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkab231 · Cited by 58
The alteration of the gut microbiome by immunosuppressive agents used in solid organ transplantation
Gibson, C. M., Childs‐Kean, L. M., Naziruddin, Z., & Howell, C. K. (2020) · Transplant Infectious Disease · doi:10.1111/tid.13397 · Cited by 56
Czepiel, J., Krůtová, M., Mizrahi, A., Khanafer, N. L., Enoch, D., Patyi, M., Deptuła, A., Agodi, A., Nuvials, X., Pituch, H. M., et al. (2021) · Antibiotics · doi:10.3390/antibiotics10030299 · Cited by 63
Oral fosfomycin for the treatment of chronic bacterial prostatitis
Karaiskos, I., Galani, L., Sakka, V., Gkoufa, A., Sopilidis, O., Chalikopoulos, D., Alivizatos, G. J., & Giamarellou, E. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz015 · Cited by 56
Kechagias, K. S., Chorepsima, S., Triarides, N. A., & Falagas, M. E. (2020) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-019-03756-z · Cited by 52
“The treatment of choice for CDIs is oral vancomycin or fidaxomicin, with oral metronidazole being an alternative option [1], according to IDSA guidelines published in February 2018.”
BackgroundMethodInfluentialRode, A. A., Chehri, M., Krogsgaard, L. R., Heno, K. K., Svendsen, A. T., Ribberholt, I., Helms, M., Engberg, J., Schønning, K., Tvede, M., et al. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16309 · Cited by 53
Curcio, D., Cane, A. D., FERNÁNDEZ, F., & Correa, J. (2019) · Infectious Diseases and Therapy · doi:10.1007/s40121-019-0231-8 · Cited by 55
“associated diarrhea [11, 19] and as the main contributing factor in gastroenteritis-associated”
BackgroundArbefeville, S. S., Timbrook, T. T., & Garner, C. D. (2024) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkae275 · Cited by 75
Tariq, R., Disbrow, M. B., DiBaise, J. K., Orenstein, R., Saha, S., Solanky, D., Loftus, E. V., Pardi, D. S., & Khanna, S. (2019) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izz299 · Cited by 55
Leading Practices in Antimicrobial Stewardship: Conference Summary
Baker, D. W., Hyun, D. Y., Neuhauser, M. M., Bhatt, J., & Srinivasan, A. (2019) · The Joint Commission Journal on Quality and Patient Safety · doi:10.1016/j.jcjq.2019.04.006 · Cited by 51
Reygner, J., Charrueau, C., Delannoy, J., Mayeur, C., Robert, V., Cuinat, C., Meylheuc, T., Mauras, A., Augustin, J., Nicolis, I., et al. (2020) · Gut Microbes · doi:10.1080/19490976.2020.1759489 · Cited by 55
“Based on these trials, FMT is now strongly recommended by the European and US infectious disease societies.(8,9) Beneficial effects of FMT have also been described in case series and small prospective trials for several other conditions associated with gastrointestinal microbial dysbiosis, including inflammatory bowel…”
MethodAnti-infectious treatment duration: The SPILF and GPIP French guidelines and recommendations
Gauzit, R., Castan, B., Bonnet, É., Bru, J. P., Cohen, R., Diamantis, S., Faye, A., Hitoto, H., Issa, N., Lebeaux, D., et al. (2021) · Infectious Diseases Now · doi:10.1016/j.idnow.2020.12.001 · Cited by 72
Gut Dysbiosis and Clostridioides difficile Infection in Neonates and Adults
Vasilescu, I.-M., Chifiriuc, M. C., Pîrcălăbioru, G. G., Filip, R., Bolocan, A., Lazăr, V., Diţu, L.-M., & Bleoţu, C. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.651081 · Cited by 61
“Clinical symptoms range from mild diarrhea to fulminant colitis, known as pseudomembranous colitis, with its complications – toxic megacolon and large bowel perforation (McDonald et al., 2018; Dieterle et al., 2019).”
BackgroundThe gut microbiota in transplant patients
Chong, P. P., & Koh, A. Y. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.100614 · Cited by 58
“FMT is currently recommended for patients with rCDI only after 3 or more recurrences of infection.(59) The 2017 Update by the IDSA and SHEA Clinical Practice Guidelines for CDI currently recommends treating the first recurrence of CDI with either oral vancomycin as a pulsed and tapered regimen (weak recommendation, lo…”
BackgroundChang, L., Hsiao, C.-J., Chen, B., Liu, T.-Y., Ding, J. H., Hsu, W., Su-Ortiz, V. A., Chen, S., Su, K., Wu, H., et al. (2021) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2020-000553 · Cited by 55
Garland, M., Hryckowian, A. J., Tholen, M., Oresic Bender, K., Van Treuren, W. W., Loscher, S., Sonnenburg, J. L., & Bogyo, M. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100005 · Cited by 48
“Antibiotic selection for CDI-permissive states is even more concerning given clinical experiments showing that even one dose of antibiotics can cause long-term shifts in the GI microbiome(11) and that the antibiotics vancomycin, metronidazole, and fidaxomicin are the current standard-of-care treatments for CDI.(12,13)…”
The Gut Bacterial Community Potentiates Clostridioides difficile Infection Severity
Lesniak, N. A., Schubert, A. M., Flynn, K. J., Leslie, J. L., Sinani, H., Bergin, I. L., Young, V. B., & Schloss, P. D. (2022) · mBio · doi:10.1128/mbio.01183-22 · Cited by 53
“Patients who develop shock or hypotension, ileus, or toxic megacolon are considered to have fulminant CDI (2).”
BackgroundSchwanbeck, J., Riedel, T., Laukien, F., Schober, I., Oehmig, I., Zimmermann, O., Overmann, J., Groß, U., Zautner, A. E., & Bohne, W. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky375 · Cited by 49
Epidemiologic Trends in Clostridioides difficile Infections in a Regional Community Hospital Network
Turner, N., Grambow, S. C., Woods, C. W., Fowler, V. G., Moehring, R. W., Anderson, D. J., & Lewis, S. S. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.14149 · Cited by 52
Therapeutic Potential of Nitazoxanide: An Appropriate Choice for Repurposing versus SARS-CoV-2?
Stachulski, A. V., Taujanskas, J., Pate, S., Rajoli, R. K. R., Aljayyoussi, G., Pennington, S. H., Ward, S. A., Hong, W. D., Biagini, G. A., Owen, A., et al. (2020) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.0c00478 · Cited by 48
Mortality, Health Care Use, and Costs of Clostridioides difficile Infections in Older Adults
Feuerstadt, P., Nelson, W. W., Drozd, E. M., Dreyfus, J., Dahdal, D. N., Wong, A. C.-Y., Mohammadi, I., Teigland, C. L., & Amin, A. (2022) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2022.01.075 · Cited by 56
Update on Treatment of Clostridioides difficile Infection
Cho, J. M., Pardi, D. S., & Khanna, S. (2020) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.08.006 · Cited by 52
An Update on Clostridioides difficile Binary Toxin
Martínez-Meléndez, A., Cruz-López, F., Morfín‐Otero, R., Maldonado-Garza, H. J., & Garza‐González, E. (2022) · Toxins · doi:10.3390/toxins14050305 · Cited by 62
Wu, Z., Xu, Q., Gu, S., Chen, Y., Lv, L., Zheng, B., Wang, Q., Wang, K., Wang, S., Xia, J., et al. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.841920 · Cited by 57
Han, S., Yi, J., Kim, J., Lee, S., & Moon, H. (2019) · PLoS ONE · doi:10.1371/journal.pone.0212626 · Cited by 53
Azimirad, M., Krůtová, M., Yadegar, A., Shahrokh, S., Olfatifar, M., Aghdaei, H. A., Fawley, W. N., Wilcox, M. H., & Zali, M. R. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1780949 · Cited by 47
Self-citationKRINKO (2022) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-022-03576-1 · Cited by 61
The Role of Fecal Microbiota Transplantation in IBD
Fanizzi, F., D’Amico, F., Bombassaro, I., Zilli, A., Furfaro, F., Parigi, T. L., Cicerone, C., Fiorino, G., Peyrin‐Biroulet, L., Danese, S., et al. (2024) · Microorganisms · doi:10.3390/microorganisms12091755 · Cited by 52
“…international guidelines patients with multiple recurrences of CDI who have failed appropriate Indeed, FMT is now recommended in the CDI treatment international guidelines for patients with multiple recurrences of CDI who have failed appropriate antibiotic treatments [60]. antibiotic [60].”
Diagnosis and Treatment of Clostridium difficile Infection
Gupta, A., Cifu, A. S., & Khanna, S. (2018) · JAMA · doi:10.1001/jama.2018.12194 · Cited by 47
Nuts and Bolts of Fecal Microbiota Transplantation
Krajicek, E. J., Fischer, M., Allegretti, J. R., & Kelly, C. R. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.09.029 · Cited by 49
Self-citationWilcox, M. H., McGovern, B., & Hecht, G. A. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa114 · Cited by 49
“The Infectious Diseases Society of America/Society for Healthcare Epidemiology of America (IDSA/SHEA) guidelines recently recommended FMT for multiply recurrent CDI, despite “moderate quality” evidence, reflecting the great unmet need [14].”
InfluentialSelf-citationAbutaleb, N. S., & Seleem, M. N. (2020) · Scientific Reports · doi:10.1038/s41598-020-64882-9 · Cited by 51
Frentrup, M., Zhou, Z., Steglich, M., Meier‐Kolthoff, J. P., Göker, M., Riedel, T., Bunk, B., Spröer, C., Overmann, J., Blaschitz, M., et al. (2020) · Microbial Genomics · doi:10.1099/mgen.0.000410 · Cited by 47
Dalal, R. S., & Allegretti, J. R. (2021) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000739 · Cited by 48
Evolution of fecal microbiota transplantation in methodology and ethical issues
Zhang, F., Zhang, T., Zhu, H., & Borody, T. J. (2019) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2019.04.004 · Cited by 47
Leveraging diagnostic stewardship within antimicrobial stewardship programmes
Claeys, K. C., & Johnson, M. D. (2023) · Drugs in Context · doi:10.7573/dic.2022-9-5 · Cited by 52
Anjewierden, S., Han, Z., Foster, C. B., Pant, C., & Deshpande, A. (2019) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2019.23 · Cited by 49
Decontamination devices in health care facilities: Practical issues and emerging applications
Donskey, C. J. (2019) · American Journal of Infection Control · doi:10.1016/j.ajic.2019.03.005 · Cited by 48
Hengel, R. L., Ritter, T. E., Nathan, R. V., Anglen, L. J. V., Schroeder, C. P., Dillon, R. J., Marcella, S. W., & Garey, K. W. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa097 · Cited by 47
Self-citationFeuerstadt, P., Boules, M., Stong, L., Dahdal, D. N., Sacks, N. C., Lang, K. M., & Nelson, W. W. (2021) · SAGE Open Medicine · doi:10.1177/2050312120986733 · Cited by 46
Tixier, E. N., Verheyen, E., Ungaro, R. C., & Grinspan, A. M. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15526 · Cited by 45
D’Souza, S. M., Houston, K. V., Keenan, L., Yoo, B. S., Parekh, P. J., & Johnson, D. A. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i18.2054 · Cited by 53
Hang, Z., Lei, T., Zeng, Z., Cai, S., Bi, W., & Du, H. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112343 · Cited by 47
Ma, Y., Yang, J. Y., Peng, X., Xiao, K. Y., Xu, Q., & Wang, C. (2020) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12839 · Cited by 44
“CDAD can cause pseudomembranous colitis and toxic megacolon, and even death.(5,6) C.”
BackgroundMizusawa, M., Small, B. A., Hsu, Y., Sharara, S. L., Advic, E., Kauffman, C., Milstone, A. M., Feldman, L. S., Pahwa, A. K., Trivedi, J. B., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz295 · Cited by 44
Self-citationLiu, L., Wang, Q., Wu, X., Qi, H., Das, R., Lin, H., Shi, J., Wang, S., Yang, J., Xue, Y., et al. (2020) · Environmental Pollution · doi:10.1016/j.envpol.2020.114399 · Cited by 48
Clancy, C. J., Buehrle, D. J., Vu, M., Wagener, M. M., & Nguyen, M. H. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa484 · Cited by 44
Allegretti, J. R., Kelly, C. R., Grinspan, A. M., Mullish, B. H., Kassam, Z., & Fischer, M. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.07.045 · Cited by 44
Self-citationHospital-onset Clostridioides difficile infections during the COVID-19 pandemic
Luo, Y., Grinspan, L. T., Fu, Y., Adams-Sommer, V., Willey, D. K., Patel, G., & Grinspan, A. M. (2020) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2020.1223 · Cited by 44
Genetic Mechanisms of Vancomycin Resistance in Clostridioides difficile: A Systematic Review
Eubank, T. A., Gonzales-Luna, A. J., Hurdle, J. G., & Garey, K. W. (2022) · Antibiotics · doi:10.3390/antibiotics11020258 · Cited by 57
Self-citationSix Long-Standing Questions about Antibiotic Prophylaxis in Surgery
Sartelli, M., Boermeester, M. A., Caínzos, M., Coccolini, F., de Jonge, S. W., Rasa, H. K., Dellinger, E. P., McNamara, D. A., Fry, D. E., Cui, Y., et al. (2023) · Antibiotics · doi:10.3390/antibiotics12050908 · Cited by 60
“Antibiotic use is under scrutiny due to concerns about the emergence of antimicrobial resistance (AMR) and other hazardous side effects [20,21].”
BackgroundCommon Bacterial and Viral Infections: Review of Management in the Pregnant Patient
Winders, H. R., Gould, A. P., Eiland, L. S., Griffin, B. L., McLaughlin, M. M., Stover, K. R., Bland, C. M., & Bookstaver, P. B. (2018) · Annals of Pharmacotherapy · doi:10.1177/1060028018817935 · Cited by 47
Mewes, J. C., Pulia, M. S., Mansour, M. K., Broyles, M. R., Nguyen, H. B., & Steuten, L. (2019) · PLoS ONE · doi:10.1371/journal.pone.0214222 · Cited by 50
Fecal microbiota transplantation (FMT) for C. difficile infection, just say ‘No’
Tan, X., & Johnson, S. (2019) · Anaerobe · doi:10.1016/j.anaerobe.2019.102092 · Cited by 49
Self-citationHourigan, S. K., Ahn, M., Gibson, K. M., Pérez-Losada, M., Felix, G., Weidner, M., Leibowitz, I., Niederhuber, J. E., Sears, C. L., Crandall, K. A., et al. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofz379 · Cited by 43
Allegretti, J. R., Marcus, J., Storm, M., Sitko, J., Kennedy, K., Gerber, G. K., & Bry, L. (2020) · Digestive Diseases and Sciences · doi:10.1007/s10620-019-05900-3 · Cited by 43
“Additionally, in the newest 2018 Infectious Diseases Society of America guidelines [4], changes in diagnostic laboratory testing for C.”
BackgroundMethodDiagnosis and Treatment of Clostridioides ( Clostridium ) difficile Infection in Adults in 2020
Rao, K. K., & Malani, P. (2020) · JAMA · doi:10.1001/jama.2019.3849 · Cited by 43
Ochoa‐Hein, E., Rajme‐López, S., Rodríguez‐Aldama, J. C., Huertas-Jiménez, M. A., Chávez-Ríos, A. R., Paz-García, R. D., Haro-Osnaya, A., González-Colín, K. K., González-González, R., González-Lara, M. F., et al. (2020) · American Journal of Infection Control · doi:10.1016/j.ajic.2020.12.008 · Cited by 44
“difficile.(3,4) No modification of our cleaning and disinfection process was needed; the high concentration of sodium hypochlorite used was active against C.”
Wei, S., Bahl, M. I., Baunwall, S. M. D., Dahlerup, J. F., Hvas, C. L., & Licht, T. R. (2022) · Gut Microbes · doi:10.1080/19490976.2022.2084306 · Cited by 47
Tieroshyn, V., Мороз, Л. В., Pryshliak, O. Y., Shostakovich-Koretska, L., Kruglova, O., & Gordienko, L. (2020) · Scientific Reports · doi:10.1038/s41598-020-62386-0 · Cited by 64
Probiotics: insights and new opportunities for Clostridioides difficile intervention
Pal, R., Athamneh, A. I. M., Deshpande, R., Ramirez, J. A. R., Adu, K. T., Muthuirulan, P., Pawar, S., Biazzo, M., Apidianakis, Y., Sundekilde, U. K., et al. (2022) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2022.2072705 · Cited by 51
“Current therapeutic options for mild-to-moderate CDI cases include the glycopeptide vancomycin or the macrolide fidaxomicin (McDonald et al. 2018; van Prehn et al. 2021).”
BackgroundSystems and synthetic biology-driven engineering of live bacterial therapeutics
Kim, K., Kang, M., & Cho, B. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1267378 · Cited by 54
Management of Clostridioides difficile Infection: Diagnosis, Treatment, and Future Perspectives
Cymbal, M., Chatterjee, A. B., Baggott, B. B., & Aurón, M. (2024) · The American Journal of Medicine · doi:10.1016/j.amjmed.2024.03.024 · Cited by 63
Clostridioides difficile Toxins: Host Cell Interactions and Their Role in Disease Pathogenesis
Alam, M. Z., & Madan, R. (2024) · Toxins · doi:10.3390/toxins16060241 · Cited by 42
“…therapies do provide a good initial cure, unfortunately, antibiotics that can eradicate C. difficile bacteria can also impact the indigenous gut microbiota, and these therapies create an ideal niche for the growth of C. difficile bacteria, resulting in high rates of recurrent infections [87,88].”
BackgroundSepsis in Immunocompromised Patients Without Human Immunodeficiency Virus
McCreery, R., Florescu, D. F., & Kalil, A. C. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa320 · Cited by 46
Poylin, V. Y., Hawkins, A. T., Bhama, A. R., Boutros, M., Lightner, A. L., Khanna, S., Paquette, I. M., & Feingold, D. L. (2021) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000002047 · Cited by 50
Chen, H., Zeng, Y.-B., Zhang, Z., Kong, C., Zhang, S., Li, Z., Huang, J., Xu, Y., Mao, Y., Cai, P., et al. (2021) · Journal of Inflammation Research · doi:10.2147/jir.s337031 · Cited by 42
Cruz, K. C. P., Enekegho, L. O., & Stuart, D. T. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.890479 · Cited by 50
Gut Microbiota Composition and Cardiovascular Disease: A Potential New Therapeutic Target?
Belli, M., Barone, L., Longo, S., Prandi, F. R., Lecis, D., Mollace, R., Margonato, D., Muscoli, S., Sergi, D., Federici, M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241511971 · Cited by 47
Fecal microbiota transplantation: a tale of two regulatory pathways
Hoffmann, D. E., Javitt, G. H., Kelly, C. R., Keller, J. J., Baunwall, S. M. D., & Hvas, C. L. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2493901 · Cited by 49
Self-citationLin, S. C., Alonso, C. D., & Moss, A. C. (2018) · Transplant Infectious Disease · doi:10.1111/tid.12967 · Cited by 44
Morrisette, T., Matre, A. V., Miller, M. A., Mueller, S. W., Bajrovic, V., Abidi, M. Z., Benamu, E., Kaiser, J. N., Barber, G. R., Chase, S., et al. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.06.021 · Cited by 39
Stevens, V. W., Khader, K., Echevarria, K. L., Nelson, R. E., Zhang, Y., Jones, M., Timbrook, T. T., Samore, M. H., & Rubin, M. A. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz871 · Cited by 42
Okumura, H., Fukushima, A., Taieb, V., Shoji, S., & English, M. (2019) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2019.07.005 · Cited by 41
Lomeli, B., Galbraith, H., Schettler, J., Saviolakis, G. A., Elamin, W. F., Osborn, B. L., Ravel, J., Hazleton, K. Z., Lozupone, C., Evans, R. J., et al. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01395-19 · Cited by 41
“Clostridioides difficile infection (CDI) is currently classified as an urgent threat by the CDC as the leading cause of antibiotic-associated diarrhea among hospitalized patients (1, 2) and the most common cause of health care-associated infections in the Citation Lomeli BK, Galbraith H, Schettler J, Saviolakis GA, El…”
BackgroundAbutaleb, N. S., & Seleem, M. N. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02115-19 · Cited by 44
“unable to obtain or be treated with vancomycin or fidaxomicin (6).”
BackgroundCold, F., Baunwall, S. M. D., Dahlerup, J. F., Petersen, A. M., Hvas, C. L., & Hansen, L. H. (2021) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848211041004 · Cited by 42
Use of Race in Pediatric Clinical Practice Guidelines: A Systematic Review
Gilliam, C. A., Lindo, E. G., Cannon, S. T., Kennedy, L., Jewell, T. E., & Tieder, J. S. (2022) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2022.1641 · Cited by 42
Management of fever and neutropenia in the adult patient with acute myeloid leukemia
Peseski, A. M., McClean, M., Green, S. D., Beeler, C., & Koenig, H. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2020.1820863 · Cited by 44
Scott, M. M., & Liang, S. Y. (2021) · Emergency Medicine Clinics of North America · doi:10.1016/j.emc.2021.01.004 · Cited by 44
Momani, L. A. A., Abughanimeh, O. K. M., Boonpherg, B., Gabriel, J. G., & Young, M. (2018) · Cureus · doi:10.7759/cureus.2778 · Cited by 40
Diorio, C. J., Robinson, P. D., Ammann, R. A., Castagnola, E., Erickson, K., Esbenshade, A. J., Fisher, B. T., Haeusler, G. M., Kuczynski, S., Lehrnbecher, T., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.00407 · Cited by 40
Tabak, Y. P., Srinivasan, A., Yu, K. C., Kurtz, S. G., Gupta, V., Gelone, S. P., Scoble, P. J., & McDonald, L. C. (2019) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2019.236 · Cited by 41
Self-citationShao, X., AbdelKhalek, A., Abutaleb, N. S., Velagapudi, U. K., Yoganathan, S., Seleem, M. N., & Talele, T. T. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01198 · Cited by 40
Deshpande, A., Wu, X., Huo, W., Palmer, K. L., & Hurdle, J. G. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00415-20 · Cited by 40
“The health care impact of the epidemic C. difficile strains is evident from there being about half a million cases of CDI and ∼29,000 deaths in the United States in 2011 (1, 2).”
MethodInfluentialUltrapotent Inhibitor of Clostridioides difficile Growth, Which Suppresses Recurrence In Vivo
Naclerio, G. A., Abutaleb, N. S., Li, D., Seleem, M. N., & Sintim, H. O. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01198 · Cited by 42
Polívková, S., Krůtová, M., Čapek, V., Sýkorová, B., & Beneš, J. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.11.004 · Cited by 44
Garey, K. W., McPherson, J. K., Dinh, A. Q., Hu, C., Jo, J., Wang, W., Lancaster, C. K., Gonzales-Luna, A. J., Loveall, C., Begum, K., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac096 · Cited by 40
Self-citationZhu, L. J., Liu, A. Y., Wong, P. H., & Arroyo, A. C. (2022) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-021-08919-5 · Cited by 52
Zhang, J., Chen, L., Gomez‐Simmonds, A., Yin, M. T., & Freedberg, D. E. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01129-22 · Cited by 39
Metadata
- Authors
- McDonald, L. C., Gerding, D. N., Johnson, S., Bakken, J. S., Carroll, K. C., Coffin, S. E., Dubberke, E. R., Garey, K. W., Gould, C. V., Kelly, C., Loo, V., Shaklee Sammons, J., Sandora, T. J., & Wilcox, M. H.
- Affiliations
- Centers for Disease Control and Prevention (US)
- Edward Hines, Jr. VA Hospital (US)
- Loyola University Medical Center (US)
- St. Luke's Hospital (US)
- Johns Hopkins University (US)
- Children's Hospital of Philadelphia (US)
- Washington University in St. Louis (US)
- University of Houston (US)
- Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
- McGill University Health Centre (CA)
- Children’s Hospital of Philadelphia, Pennsylvania
- Boston Children's Hospital (US)
- Leeds Teaching Hospitals NHS Trust (GB)
- Corresponding author
- McDonald, L Clifford
- ORCID
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-02-15
- Volume
- 66
- Issue
- 7
- Pages
- e1-e48
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- PMC
- PMC6018983
- OpenAlex
- W2791326569
- Cited by
- 2,690
- References
- 383
- Citations by year
- 2026: 148 · 2025: 179 · 2024: 215 · 2023: 305 · 2022: 331 · 2021: 423 · 2020: 486 · 2019: 408 · 2018: 185
- FWCI
- 228.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Infectious Diseases (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (submittedVersion)
- Funders
- Agency for Health Research and Quality
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
- Health Sciences › Medicine › Infectious Diseases › Infection Control in Healthcare
- Health Sciences › Medicine › Microbiology (medical) › Bacterial Identification and Susceptibility Testing
- Keywords
- Clostridium difficile infection, nosocomial infections, healthcare-associated diarrhea, pediatric infection, diagnosis, treatment, infection control, environmental management, ribotype 027, community-acquired infections, epidemiology
- MeSH terms
- Adult, Child, Clostridium Infections, Diarrhea, Humans, Retrospective Studies, Societies, Societies, Medical, Clostridioides difficile, Infectious Disease Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.